History and Current Status of Polymyxin B-immobilized Fiber Column for Treatment of Severe Sepsis and Septic Shock

Overview

Journal Ann Gastroenterol Surg

Date 2018 Jun 5

PMID 29863114

Citations 14

Authors

Tomoharu Shimizu

Toru Miyake

Masaji Tani

Affiliations

Soon will be listed here.

Abstract

Toraymyxin (Toray Medical Co., Ltd, Tokyo, Japan) has been developed as a direct hemoperfusion column that contains polymyxin B-immobilized fiber to bind endotoxins in patients' blood. Toraymyxin was approved by the Japanese National Health Insurance system for the treatment of endotoxemia and septic shock in 1994. Since then, PMX (defined as direct hemoperfusion with Toraymyxin) has been safely used in more than 100 000 cases in emergency and intensive care units in Japan. Toraymyxin is currently available for use in clinical settings in 12 countries outside of Japan. We reviewed and analyzed the development, clinical use, and efficacy of Toraymyxin, and assessed the current status of Toraymyxin use for the treatment of severe sepsis and septic shock. Our review shows that PMX appeared to be effective in improving hemodynamics and respiratory function in septic shock requiring emergency abdominal surgery. Recent large-scale ranomized controlled trialscould not demonstrate whether prognosis is improved by PMX. However, the latest meta-analysis revealed that PMX significantly decreased mortality in patients with severe sepsis and septic shock. Combination of PMX with continuous hemodiafiltration and longer duration of PMX might be an effective strategy to improve survival in such patients.

Citing Articles

Extracorporeal therapies in sepsis: a comprehensive review of the Selective Cytopheretic Device, Polymyxin B and Seraph cartridges.

Yessayan L, Pino C, Humes H Ren Fail. 2025; 47(1):2459349.

PMID: 39962644 PMC: 11837919. DOI: 10.1080/0886022X.2025.2459349.

The role of endotoxin in septic shock.

Kellum J, Ronco C Crit Care. 2023; 27(1):400.

PMID: 37858258 PMC: 10585761. DOI: 10.1186/s13054-023-04690-5.

Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility.

Damianaki A, Stambolliu E, Alexakou Z, Petras D Kidney Res Clin Pract. 2023; 42(3):298-311.

PMID: 37098671 PMC: 10265212. DOI: 10.23876/j.krcp.22.223.

Targeting circulating high mobility group box-1 and histones by extracorporeal blood purification as an immunomodulation strategy against critical illnesses.

Li Y, Chen Y, Yang T, Chang K, Deng N, Zhao W Crit Care. 2023; 27(1):77.

PMID: 36855150 PMC: 9972334. DOI: 10.1186/s13054-023-04382-0.

Rationale for sequential extracorporeal therapy (SET) in sepsis.

Ronco C, Chawla L, Husain-Syed F, Kellum J Crit Care. 2023; 27(1):50.

PMID: 36750878 PMC: 9904264. DOI: 10.1186/s13054-023-04310-2.

References

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Aoki H, Kodama M, Tani T, Hanasawa K . Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg. 1994; 167(4):412-7. DOI: 10.1016/0002-9610(94)90126-0. View

Iwagami M, Yasunaga H, Doi K, Horiguchi H, Fushimi K, Matsubara T . Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med. 2013; 42(5):1187-93. DOI: 10.1097/CCM.0000000000000150. View

Shoji H . Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003; 7(1):108-14. DOI: 10.1046/j.1526-0968.2003.00005.x. View

Anspach F . Endotoxin removal by affinity sorbents. J Biochem Biophys Methods. 2001; 49(1-3):665-81. DOI: 10.1016/s0165-022x(01)00228-7. View

Yamashita C, Hara Y, Kuriyama N, Nakamura T, Nishida O . Clinical Effects of a Longer Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion Therapy for Severe Sepsis and Septic Shock. Ther Apher Dial. 2015; 19(4):316-23. DOI: 10.1111/1744-9987.12339. View

Shimizu T, Obata T, Sonoda H, Akabori H, Tabata T, Eguchi Y . The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin B-immobilized fiber column in patients with septic shock. Transfus Apher Sci. 2013; 49(3):499-503. DOI: 10.1016/j.transci.2013.04.042. View

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165-228. PMC: 7095153. DOI: 10.1007/s00134-012-2769-8. View

Payen D, Guilhot J, Launey Y, Lukaszewicz A, Kaaki M, Veber B . Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41(6):975-84. PMC: 4477725. DOI: 10.1007/s00134-015-3751-z. View

10.

Antonelli M, Ronco C . Polymyxin B hemoperfusion in sepsis: growing body of evidence and occasional conflicting results. Blood Purif. 2015; 39(1-3):I-II. DOI: 10.1159/000431018. View

11.

Shimizu T, Hanasawa K, Sato K, Umeki M, Koga N, Naganuma T . Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch Surg. 2008; 394(2):303-11. DOI: 10.1007/s00423-008-0395-2. View

12.

Tokumasu H, Watabe S, Tokumasu S . Effect of hemodiafiltration therapy in a low-birthweight infant with congenital sepsis. Pediatr Int. 2015; 58(3):237-240. DOI: 10.1111/ped.12776. View

13.

Foster D, Klein D, Guadagni G, Walker P . Endotoxin removal: bringing the mission to North America. Blood Purif. 2014; 37 Suppl 1:14-7. DOI: 10.1159/000356832. View

14.

Romaschin A, Harris D, Ribeiro M, Paice J, Foster D, Walker P . A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods. 1998; 212(2):169-85. DOI: 10.1016/s0022-1759(98)00003-9. View

15.

Vincent J, Laterre P, Cohen J, Burchardi H, Bruining H, Alvarez Lerma F . A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005; 23(5):400-5. DOI: 10.1097/01.shk.0000159930.87737.8a. View

16.

Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y . Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher. 2002; 6(3):234-40. DOI: 10.1046/j.1526-0968.2002.00416.x. View

17.

Antonelli M, Fumagalli R, Cruz D, Brienza N, Giunta F . PMX endotoxin removal in the clinical practice: results from the EUPHAS trial. Contrib Nephrol. 2010; 167:83-90. DOI: 10.1159/000315922. View

18.

Cruz D, Perazella M, Bellomo R, De Cal M, Polanco N, Corradi V . Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007; 11(2):R47. PMC: 2206475. DOI: 10.1186/cc5780. View

19.

Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochiai R . The Japanese guidelines for the management of sepsis. J Intensive Care. 2015; 2(1):55. PMC: 4336273. DOI: 10.1186/s40560-014-0055-2. View

20.

Cutuli S, Artigas A, Fumagalli R, Monti G, Ranieri V, Ronco C . Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016; 6(1):77. PMC: 4977232. DOI: 10.1186/s13613-016-0178-9. View